Antiviral Agents

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention introduces a novel approach to treating and preventing retroviral infections (especially HIV and related viruses) by inhibiting the degradation of the viral protein p6 within host cells. The key concept is that the Insulin-Degrading Enzyme (IDE) breaks down p6, a process that assists viral replication and infectivity. By using specific inhibitors of IDE (such as the molecule 6bK, insulin, or certain antibiotics), the stability of p6 is increased, which in turn significantly reduces viral replication and infectivity. The invention also covers pharmaceutical formulations and methods for screening other compounds that block p6 degradation.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of HIV-1 and HIV-2 infections in humans.
• Prophylaxis (prevention) of AIDS and its complications in HIV-infected patients.
• Combination therapy with existing antiretrovirals (HAART) to reduce drug resistance and improve efficacy.
• Treatment or prevention of retroviral infections in animals (e.g., FIV in cats, SIV in monkeys).
• Development of new antiviral drugs targeting IDE for retroviruses beyond HIV, including veterinary pathogens.
• Adjuvant therapy to lower side effects or resistance to current HIV medications.
• Screening of potential IDE inhibitors as antiviral agents.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets a previously unexplored mechanism in HIV and retroviral therapy (the IDE-mediated p6 degradation pathway).
• Potential to reduce viral replication and infectivity even when resistance to existing HIV drugs is present.
• Can be used in combination with standard antiretroviral therapies for additive or synergistic effects.
• May help reduce the emergence of drug-resistant viral strains.
• Offers a new class of molecules (IDE inhibitors like 6bK) for pharmaceutical development.
• Applicability to human and veterinary medicine, broadening its impact.
• In vitro and in vivo data suggest effective and dose-dependent inhibition of viral growth and infectivity.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to the use of a number of substances or substance groups for the treatment of retroviral infectious diseases and for the prophylaxis of their manifestation, in particular to the use of 6bK. Furthermore, a new principle of action is disclosed.